Viridian Therapeutics (VRDN) Corporate Presentation summary

Strategic vision and market focus

• Aims to lead in autoimmune diseases, starting with thyroid eye disease (TED), addressing unmet needs and expanding patient access.

• Building a diversified TED portfolio with veligrotug (IV), elegrobart (SC), and a TSHR inhibitor, with plans for pipeline expansion into other autoimmune indications.

• TED market is valued at ~$2B annually, with low penetration and high demand for new, convenient therapies.

• Launch preparations include experienced leadership, strong KOL relationships, and a focused sales strategy targeting ~2,000 core prescribers.

Clinical development and trial results

• Veligrotug demonstrated robust efficacy in two phase 3 trials (THRIVE, THRIVE-2), meeting all primary and secondary endpoints in both active and chronic TED.

• Achieved rapid onset of effect, significant proptosis and diplopia improvements, and strong durability, with 70% of responders maintaining benefit at 52 weeks.

• Veligrotug was generally well-tolerated, with low rates of hearing impairment and no treatment-related serious adverse events.

• Elegrobart, a subcutaneous anti-IGF-1R, shares the same binding domain as veligrotug and is being evaluated in phase 3 REVEAL trials for both active and chronic TED, with topline data expected in Q1 and Q2 2026.

• Phase 1 data for elegrobart showed extended half-life, sustained IGF-1 levels, and a favorable safety profile.

Pipeline and future catalysts

• Veligrotug has a PDUFA target date of June 30, 2026, with potential for rapid commercial adoption if approved.

• Elegrobart is the only remaining autoinjector SC product in phase 3 for TED, offering transformative convenience and potential market expansion.

• TSHR inhibitor IND submission anticipated in Q4 2026, targeting TED and Graves’ disease.

• FcRn inhibitor portfolio (VRDN-006, VRDN-008) targets broader autoimmune markets, with VRDN-008 showing deeper and more sustained IgG reduction and longer half-life in NHP studies compared to efgartigimod.

• FcRn market for MG and CIDP projected to exceed $11B by 2030, with Viridian’s portfolio positioned to capture significant share.